Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-BAI3 is a novel, short isoform of the adhesion G-protein-coupled receptor BAI3 (encoded by the ADGRB3 gene). It originates from an alternative promoter located in intron 17 of the ADGRB3 gene and is predominantly expressed in the human brain. Unlike the full-length BAI3 (FL-BAI3), which is membrane-bound, S-BAI3 is preferentially localized to intracellular compartments. In glioblastoma multiforme (GBM), S-BAI3 is epigenetically silenced through hypermethylation of its regulatory regions. Research indicates that S-BAI3 acts as a potent tumor suppressor; its overexpression in GBM cell lines significantly reduces proliferation, migration, and invasion. Mechanistically, S-BAI3 reverses the epithelial-to-mesenchymal transition (EMT) signature and promotes a mesenchymal-to-epithelial shift. In vivo studies using orthotopic mouse models have shown that S-BAI3 significantly attenuates tumor growth and confers a survival benefit, making it a potential target for isoform-specific epigenetic reactivation or therapeutic delivery in glioblastoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-BAI3.